medication of all patients and 1 hour after that echocardiograpdic parameters was measured again, and the results were compared. RESULTS: Peak pulmonary artery pressure and pulmonary acceleration time (PAT) significantly improved 1 hour after 100 mg oral single dose of Sildenafil (p < 0.005, 95% CI 5.41-22.93 and p = 0.005 95% CI -12.89-2.95 respectively). In addition although the right heart dimensions (right atrium & ventricle) showed a trend toward improvement, but were not statistically significant (p = 0.135, p = 0.08 respectively). CONCLUSION: These results suggest that Sildenafil has a acute significant improvement effect on PAP and PAT in patients with PPH.
Lloyd AC, Holman AJ Fourth Hurdle Consulting, London, UK OBJECTIVES: Community Acquired Pneumonia (CAP) is a leading cause of hospitalisation and mortality in industrialised countries. This study was an economic evaluation comparing moxifloxacin with a combination of levofloxacin plus ceftriaxone in patients hospitalised with CAP in Germany. METHODS: The MOTIV trial was a multinational, prospective, randomized, double-blind study in adults with CAP requiring hospitalisation and parenteral antibiotic therapy. Patients were randomised to either moxifloxacin (N = 368), or levofloxacin plus ceftriaxone (N = 365) and received sequential treatment with intravenous followed by oral antibiotics for 7-14 days. The primary effectiveness endpoint was clinical response 5-7 days after completion of treatment. Resource use recorded included length of stay, ward type, investigations and procedures performed and dose and frequency of study drug used. Costs were calculated from a German hospital perspective, drug costs were taken from the Rote Liste and other costs from a recent publication. A stochastic sensitivity analysis was performed. RESULTS: Mean age was 65 years (range 18-101) and 58% of patients had severe CAP. The percentage of patients reporting clinical response (moxifloxacin: 80%, comparator: 84%) met criteria for clinical equivalence so a cost-minimisation analysis was performed. Mean per patient cost was €2190 (95% CI: €1954, €2463) for the moxifloxacin group, and €2619 (95% CI: €2422, €2832) for the comparator group, difference (-€430, 95% CI: -€740, -€138). Medication costs were significantly lower for moxifloxacin than comparator (-€470, 95% CI: -€522, -€421) but accounted for only 15-30% of total costs. Subgroup analysis of patients with COPD, cardiovascular disease, microbiologically proven pneumonia, or severe CAP at baseline produced consistent findings. Average cost was sensitive to price paid for study drugs and the daily cost of hospital stay. CONCLUSION: Treatment with moxifloxacin was significantly less costly than treatment with levofloxacin plus ceftriaxone, with no clinically significant difference in outcomes achieved. The OLIN Studies, Luleå, Sweden OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is one of the most common chronic and disabling diseases worldwide. The objectives of this study were to measure the societal costs of COPD including both direct and indirect costs, and to estimate the costs for different severity grades of disease according to changed Swedish guidelines. METHODS: A welldefined and representative cohort of subjects was used to examine the costs of COPD. Regular telephone interviews were done with 212 subjects derived from the OLIN-Studies in northern Sweden. The severity grades of COPD were divided according to changed Swedish guidelines, and furthermore Mild COPD (FEV1 50-79% of predicted) was divided into three sub-groups, Mild I, II and III. RESULTS: A positive relationship was found between costs and severity grades of COPD, patients with lower FEV1 % of predicted normal being significantly more expensive. Furthermore, the total costs differed significantly between the Mild and Pre-clinical severity groups, from a mean value of SEK 2,513 per subject in the Pre-clinical group to SEK 28,463 for subjects having FEV1 50-59% of predicted. The same pattern was found both in direct and indirect costs. Costs for medicines and hospitalisations increased significantly according to FEV1 values in the Mild and Preclinical groups of disease. Costs for disability pension among indirect costs showed a similar trend. The annual total costs for Severe (FEV1 < 30% of predicted), Moderate (30-49%), Mild I (50-59%), Mild II (60-69%), Mild III (70-79%), and Preclinical COPD (>79%) were SEK 183, 474, 70, 609, 28, 463, 11, 527, 6 ,287 and 2,513, respectively. CONCLUSION: Large variations were found in both the level and breakdown of costs for COPD, mainly depending on the severity of the disease. When dividing mild COPD into three different severity grades of disease, we also found a positive relationship between costs and severity of disease.
PRS3 COSTS OF COPD IN SWEDEN ACCORDING TO DISEASE SEVERITY

PRS4 RELATIONSHIP BETWEEN TIME OF DURATION OF COPD AND FREQUENCY OF DISEASE EXACERBATIONS
Jahnz-Rozyk K, Targowski T, From S Military Institute of Health Service, Warsaw, Poland OBJECTIVES: Assessment of the influence of nicotine addiction, time of duration and severity of COPD on the frequency of exacerbations. METHODS: 71 patients with moderate-tosevere COPD (30 with moderate and 41 with severe) were enrolled to the study. The smoking status, FEV1 value, time of duration of COPD, and a one-year history of incidence of exacerbations were assessed in all the subjects. The relationship between the number of exacerbations and the studied features was evaluated with the regression model. RESULTS: Thirteen (18.3%) subjects were current smokers, 9 (12.7%) had never smoked and 50 (70%) had smoked in the past. The mean intensity of cigarette smoking amounted to 34.7 pack-years . The mean time of COPD duration was 9.2 [CI: 7.7-10.8] years, the mean frequency of exacerbation-3.1 [CI: 2.5-3.6] per year, and the mean % value of FEV1 was 48.1% [CI: 43.7-52.5]. There was no significant relationship between the frequency of exacerbations and the number of pack-years, smoking status, % value of FEV1 and severity of COPD. A significant correlation was observed between the time of duration of COPD and average number of exacerbations (r = 0.31, p = 0.009). It was calculated that each successive year of COPD duration is associated with 3% accumulation of exacerbation risk (determination coefficient-R2 = 0.03). CON-CLUSION: Long-time duration of COPD is related to a significant increase of the risk of COPD exacerbations-the key drivers in the overall costs of the disease. Abstracts A307
